

AMENDMENTS TO THE CLAIMS

1. (Canceled)

2-5. (Canceled)

6. (Presently Amended) A fusion polypeptide, comprising an amino acid sequence derived from a non-VGF gene fused to the amino acid sequence of SEQ ID NO: 7 ~~consisting of the polypeptide of claim 1 fused to a heterologous amino acid sequence.~~

7. (Presently Amended) The fusion polypeptide of Claim 6, wherein the amino sequence derived from a non-VGF gene encodes heterologous sequence ~~is an IgG constant domain or fragment thereof.~~

8. (Previously Amended) A composition comprising the polypeptide of Claim ~~1~~6 and a pharmaceutically acceptable formulation agent.

C1
9. (Original) The composition of Claim 8 wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant.

10-11. (Canceled)

12. (Presently Amended) The polypeptide of Claim ~~11~~6, which is covalently modified with a water-soluble polymer, wherein the water-soluble polymer that ~~is selected from the group consisting of polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, and or polyvinyl alcohol.~~

13. (Presently Amended) The polypeptide of Claim ~~12~~6 wherein the water-soluble polymer is selected ~~from the group consisting of polyethylen glycol and or dextran.~~

c/ 14-21. (Canceled)
